We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Cell Count Performed at Bedside with Innovative Biochip

By LabMedica International staff writers
Posted on 05 Jan 2016
There is a great need for an automated, portable point-of-care blood cell counter that could yield results in a matter of minutes from a drop of blood without any trained professionals to operate the instrument.

Expensive hematology analyzers are currently used as a gold standard for acquiring complete blood cell counts (CBCs) and for nearly all CBCs performed today, the patient must travel to either a hospital with a large laboratory or to a centralized laboratory testing facility.

Scientists at the University of Illinois at Urbana-Champaign (UIUC; Champaign, IL, USA) developed microfluidic biochips capable of a partial CBC using only a drop of whole blood. More...
Total leukocyte and their 3-part differential count are obtained from 10 mL of blood after on-chip lysing of the red blood cells (RBCs) and counting of the leukocytes electrically using microfabricated platinum electrodes. For RBCs and platelets, one mL of whole blood is diluted with phosphate buffered saline (PBS) on-chip and the cells are counted electrically. The total time for measurement is under 20 minutes.

The team is already developing a portable prototype of the cell counter. The base unit of the reader will likely be hand-held and will take cartridges about the size of a credit card. They estimate the cost of a test will be around USD 10 instead of the USD 100 that a current test costs. The technology is scalable and the team also plans to investigate using it in other areas, such as animal diagnostics, blood transfusion analysis, and blood cell counting for managing chemotherapy treatments.

Umer Hassan, PhD, the first author of the study and an expert in bioelectronics, said, “There is huge potential for commercializing the technology and the translation of our technology will result in minimal to no experience requirement for device operation. Even, patients can perform the test at the comfort of their home and share the results with their primary care physicians via electronic means too.” The study was published on December 11, 2015, in the journal Technology.

Related Links:

University of Illinois at Urbana-Champaign 



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Hematology Consumables
Bioblood Devices
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.